Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma

BACKGROUND: Immune checkpoint inhibitors (ICI) induce a range of immune-related adverse events (irAEs) with various degrees of severity. While clinical experience with ICI retreatment following clinically significant irAEs is growing, the safety and efficacy are not yet well characterized. METHODS:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Principais autores: Abou Alaiwi, Sarah, Xie, Wanling, Nassar, Amin H, Dudani, Shaan, Martini, Dylan, Bakouny, Ziad, Steinharter, John A, Nuzzo, Pier Vitale, Flippot, Ronan, Martinez-Chanza, Nieves, Wei, Xiao, McGregor, Bradley A, Kaymakcalan, Marina D, Heng, Daniel Y C, Bilen, Mehmet A, Choueiri, Toni K, Harshman, Lauren C
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7057439/
https://ncbi.nlm.nih.gov/pubmed/32066646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000144
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados